diagnost tool
diagnost tool
price close busi may
best best smid cap preview
buyer gh
guardant drove tremend top line growth
respect acknowledg unclear pro-
forma revenu growth rate lot one easi respons specif
believ compani good posit exceed consensu revenue
estim gh respect buyer gh
ahead call thursday top pick coverag
univers primarili sinc stock trade street revenu well
peer univers said guardant may biggest monster-to-b
coverag given peg global tam least billion
gh recent launch coverag see upsid stock
sever near-term catalyst guardant make inroad global tam peg
least look transit late-stag liquid biopsi test early-
stage liquid biopsi screen look rev adj lp
y/i vs street model volum
y/i assum clinic test y/i pharma test y/
believ like upsid gh revenue volum guid
y/i test y/i look updat relat time
submiss fda vs mid-year guid time clia
launch pan-canc medicar coverag expect
acog annual meet wrap earlier week awar
new bulletin average-risk nipt hope obtain new bulletin
around end june mid-year past month made
lot progress oncolog organ transplant reject test despit attent
execut well core nipt carrier screen busi highlight
pre-announce y/i volum beat buyer
expect deliv revenu volum within pre-announce revenue rang
y/i volum y/i prior
y/i volum model pharma revenu expect
cumul pharma contract look updat relat
time averag risk nipt bulletin acog follow acog annual meet
sourc ntra strong volum growth pharma expect
beyond follow fda grant breakthrough devic design signatera
time we signatera launch opex/spend plan follow recent
rais estim pro-forma cash end
fast-grow precis medicin big tam risk
relat reimburs fda today expect solid growth continu
remain buyer stock model rev vs street
look consum rev instrument rev
servic lab acceler rev y/i look color
earli launch new planar array system began ship april
grow number public highlight simoa technolog new
partnership includ cdx pharma ivd diagnost
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin may et
date time product may et
pt use multipl revenu estim million discount back year discount rate
use dilut share outstand model revenu growth y/i ep gross margin
oper margin
pt use multipl adj ep estim
pt use multipl revenu estim y/i discount back two year discount rate
pro-forma dilut share outstand
pt use ev/sal multipl revenu estim discount back three year discount
rate share outstand
risk achiev target price valuat
premium valuat gh trade premium multipl rel mani diagnost compani given gh best class liquid
biopsi portfolio huge believ valuat warrant bad news regulatori reimburs time product
launch shortfal financi could result lower move stock
risk obtain fda approv flagship test pan-canc label current ldt
gh take assay fda expedit access pathway via breakthrough devic design eap design
expect give prioriti review access senior fda offici doesnt guarante approv guardant view fda approv
signific mileston need facilit commerci adopt extend approv timelin would pose risk
risk obtain pan-canc medicar coverag today gh medicar coverag nsclc guardant
expect obtain pan-canc medicar coverag base expect fda approv guardant expect nation
coverag determin ncd test delay obtain pan-canc coverag would limit compani opportun
risk obtain fda approv guardantomni guardant recent launch guardant omni research use intend
take guardantomni fda obtain fda approv delay time rel expect could limit
compani opportun revenu
manag execut risk given technic natur develop liquid biopsi gh commerci success depend
manag abil launch new panel secur addit reimburs regulatori new label win
provid guidanc shortfal rel guid mark materi risk
risk launch commerci compani largest market opportun gh peg market opportun
high risk individu huge opportun primarili requir strong data gh releas promis pilot
data rel small sampl size guardant experi setback poor result delay/cancel launch
gh growth potenti would significantli reduc
diagnost tool
competit guardant compet directli compani provid comprehens genom profil therapi select
foundat medicin roch think guardant like compet recurr monitoring/residu diseas
market among other guardant may compet screen diagnost compani includ
colorect cancer screen possibl grail launch
reimburs risk end cover live think fda approv like drive
broader payor adopt larg health insur aet other current coverag decis guardant
fail increas reimburs coverag would limit opportun
risk relat intern expans guardant offer test countri outsid establish
amea softbank facilit expans asia middl east africa engag clinic trial work japan lack
compel data regulatori setback could delay expans plan ou addit guardant could struggl facilit adopt
emerg market due pricing/reimburs test
relianc sole supplier guardant reli heavili sole sequenc provid gh activ suppli agreement
decemb automat renew thereaft contract either parti option opt agreement
notic year advanc opt gh may struggl find replac sequenc meet perform
risk relat oper larg grow lab san francisco bay area home earthquak san francisco bay area
prone earthquak larg earthquak could interrupt lab oper compani lab headquart redwood citi ca
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
panorama asp compress erod margin gross margin drop sequenti expect
margin continu erod result reduct in-network price commerci payor come on-line
expand includ averag risk patient expect mitig revenu impact asp compress drive
busi profit account though busi may suffer increas test volum outpac asp
relianc lab partner move away lab partner priorit direct sale continu sell
number refer lab partner includ arup clarient sonic unclear durabl compani lab partnership may
particularli sinc lost lab partner past certain lab choos promot anoth nipt decid offer
nipt includ recent quest
fda oversight ldt test lab-develop test ivd fda take posit author
regul test medic devic fdc act gener chosen enforc author mandat certain
ltd seek fda clearanc howev fda look regul ldt use risk-bas approach begin deem
highest-risk devic follow lower risk devic believ panorama would treat moderate-risk high-risk
among highest-risk devic fda indic high-and moderate-risk ltd market
guidelin final remain market fda review submiss expect requir
remov product market regul fda ltd remain subject uncertainti controversi
constel addit talk fda receiv clearanc constel us fda indic
constel platform may appropri review de novo classif allow market
distribut constel us convers on-going fda requir obtain regulatori clearanc
market constel softwar diagnost purpos abl secur fda clearanc compli
on-going fda regulatori requir would unabl commerci constel compani cloud-bas distribut
competit compet directli compani offer nipt carrier screen test ob/gyn mfm
market labcorp roch counsyl mani compani larger abl
leverag economi scale win busi offer multipl test servic women health one requisit form
observ research doctor often switch test brand may make market share gain difficult
strong competit oncolog uncertain time oncolog launch develop liquid biopsi test oncolog
manag size opportun billion initi sampl collect activ lung ovarian
cancer collect dozen collabor includ vanderbilt stanford columbia cancer research uk
other also initi collect effort breast cancer plan announc collabor later year
alon pursu blood-bas test oncolog market leader today substanti base revenu data
diagnost tool
counsyl trovagen pathway genom mdx name hand
ethic legal social concern relat genet inform could reduc demand genet test test provid
dna test servic like conduct use panorama expect conduct oncolog may rais ethic legal
social issu regard privaci appropri use result inform government author could social
purpos limit regul use genom inform genom test prohibit test genet predisposit certain
condit particularli known cure similarli concern may lead patient refus use genet test even
permiss ethic social concern may also complic abil protect patent technolog
import medicaid nipt approxim birth unit state state medicaid program recipi
end recogn medicaid provid state state requir compani oper lab
state becom recogn medicaid provid typic medicaid rate price medicar commonli lowest payor
term dollar
small-cap compani risk share price volatil small-cap compani low trade liquid thu may difficult
investor sell share quickli favor price rel competitor public market found lack
establish oper histori may make difficult effect compet larger competitor small-cap compani
gener less avail inform public domain make hard fulli evalu busi
access capit balanc sheet small public compani may less access capit make harder bridg
gap cash flow fuel growth opportun undertak larg capit expenditur hold cash balanc
sheet burn cash capit expenditur requir includ sale market expans research
develop exist product improv new product develop launch regulatori clearanc facil headcount
expans oper financi inform system cost unabl secur addit fund
need may delay reduc scope elimin one research develop program sale market
time profit accumul deficit expect loss continu least
next month profit reli continu top-lin growth success instrument assay launch
expans commerci organ market penetr util uptak delay instrument test launch regulatori
reimburs decis health custom purchas environ may extend goal profit
face challeng competitor face life scienc research market includ rapid technolog chang
properti disput price competit aggress market practic need invest infrastructur advanc
increas demand instrument test failur accur forecast demand would neg impact
busi abil attain profit
commerci risk market accept market accept depend compani abil improv exist product
introduc new product success prove offer novel attract altern compet technolog
face risk relat custom acquisit technolog valid sale cycl instrument/test accuraci reliabl
prove econom benefit adopt technolog success depend compani abil cater divers custom
base includ academ government research institut well biopharmaceut contract research compani
face risk relat talent acquisit expans direct sale forc abil identifi secur desir
third-parti sale distribut partner custom demand depend level research develop spend academ
government research institut biopharma compani
exclus strateg collabor licens arrang look establish strateg collabor licens
agreement third parti develop product base simoa technolog certain vitro diagnost ivd
purpos counterparti partner priorit collabor abil gener revenu
agreement may limit given exclus natur certain collabor may abl collabor other
area exclus licens effect
relianc singl contract manufactur reli singl contract manufactur locat germani manufactur
suppli simoa analyz instrument reli singl contract manufactur locat california manufactur
suppli sr-x instrument manufactur disrupt priorit project ahead delay suppli would
neg affect oper result chang manufactur would result addit cost delay
manag execut human capital- attract retain talent success includ research
develop program commerci execut larg depend continu abil identifi hire develop motiv retain
highli skill personnel area organ given complex technic natur life scienc research market
failur attract recruit retain motiv qualifi personnel may pose risk
competit life scienc research diagnost compet directli compani servic life scienc
research diagnost market includ luminex corpor mesoscal diagnost singulex gyro corpor
nanostr technolog inc upon expans health screen market siemen abbott roch ortho clinic diagnost
thermo fisher scientif face competitor hold greater brand recognit greater financi human resourc
broader product line larger sale forc distributor network larger ip portfolio establish custom base larger scale
diagnost tool
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
